Aperio Group’s Core Laboratories CLB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q4 | $8.39M | Sell |
316,366
-1,549
| -0.5% | -$31.6K | 0.02% | 626 |
|
|
2020
Q3 | $4.85M | Sell |
317,915
-12,825
| -4% | -$269K | 0.02% | 756 |
|
|
2020
Q2 | $6.72M | Buy |
330,740
+81,037
| +32% | +$1.45M | 0.02% | 609 |
|
|
2020
Q1 | $2.58M | Buy |
249,703
+159,038
| +175% | +$4.45M | 0.01% | 910 |
|
|
2019
Q4 | $3.42M | Buy |
90,665
+19,217
| +27% | +$863K | 0.01% | 871 |
|
|
2019
Q3 | $3.33M | Buy |
71,448
+4,808
| +7% | +$224K | 0.01% | 853 |
|
|
2019
Q2 | $3.48M | Buy |
66,640
+29,599
| +80% | +$1.74M | 0.01% | 847 |
|
|
2019
Q1 | $2.55M | Buy |
37,041
+6,911
| +23% | +$463K | 0.01% | 939 |
|
|
2018
Q4 | $1.8M | Buy |
30,130
+6,792
| +29% | +$586K | 0.01% | 1034 |
|
|
2018
Q3 | $2.7M | Buy |
23,338
+1,268
| +6% | +$143K | 0.01% | 897 |
|
|
2018
Q2 | $2.79M | Buy |
22,070
+2,144
| +11% | +$261K | 0.01% | 868 |
|
|
2018
Q1 | $2.16M | Buy |
19,926
+63
| +0.3% | +$6.97K | 0.01% | 968 |
|
|
2017
Q4 | $2.18M | Buy |
19,863
+8,923
| +82% | +$891K | 0.01% | 955 |
|
|
2017
Q3 | $1.08M | Buy |
10,940
+5,058
| +86% | +$490K | 0.01% | 1220 |
|
|
2017
Q2 | $596K | Buy |
5,882
+518
| +10% | +$55.8K | ﹤0.01% | 1543 |
|
|
2017
Q1 | $620K | Sell |
5,364
-970
| -15% | -$113K | ﹤0.01% | 1428 |
|
|
2016
Q4 | $760K | Buy |
6,334
+906
| +17% | +$100K | 0.01% | 1266 |
|
|
2016
Q3 | $610K | Sell |
5,428
-1,235
| -19% | -$142K | ﹤0.01% | 1341 |
|
|
2016
Q2 | $825K | Buy |
6,663
+482
| +8% | +$58.2K | 0.01% | 1153 |
|
|
2016
Q1 | $695K | Sell |
6,181
-1,477
| -19% | -$153K | 0.01% | 1208 |
|
|
2015
Q4 | $833K | Buy |
7,658
+1,240
| +19% | +$142K | 0.01% | 1094 |
|
|
2015
Q3 | $641K | Buy |
6,418
+718
| +13% | +$78.1K | 0.01% | 1171 |
|
|
2015
Q2 | $650K | Sell |
5,700
-495
| -8% | -$60K | 0.01% | 1192 |
|
|
2015
Q1 | $647K | Sell |
6,195
-314
| -5% | -$33.5K | 0.01% | 1137 |
|
|
2014
Q4 | $783K | Buy |
6,509
+1,940
| +42% | +$255K | 0.01% | 1003 |
|
|
2014
Q3 | $669K | Sell |
4,569
-68
| -1% | -$10.5K | 0.01% | 1008 |
|
|
2014
Q2 | $775K | Sell |
4,637
-177
| -4% | -$31.5K | 0.01% | 942 |
|
|
2014
Q1 | $955K | Buy |
+4,814
| New | +$909K | 0.01% | 1022 |
|
|
2013
Q4 | – | Sell |
-5,433
| Closed | -$1.01M | – | 912 |
|
|
2013
Q3 | $919K | Sell |
5,433
-214
| -4% | -$33.2K | 0.02% | 873 |
|
|
2013
Q2 | $856K | Buy |
+5,647
| New | +$800K | 0.02% | 825 |
|
Other funds holding CLB
AI
FAM
AC
Aperio Group's CLB Position: Q4 2020 in Review
Aperio Group reduced its Core Laboratories (CLB) stake by 0.49% in Q4 2020, selling an estimated $31.6K and leaving 316,366 shares worth $8.39M. The position accounts for 0.02% of the portfolio, ranked #626.
Aperio Group first reported a position in CLB in Q2 2013 and has held it in 30 quarters since. 181 funds tracked by Wall St. Rank hold CLB as of Q4 2020.
- Aperio Group held 316,366 shares of Core Laboratories worth $8.39M as of Q4 2020.
- Aperio Group sold 1,549 Core Laboratories shares in Q4 2020, an estimated $31.6K.
- Core Laboratories made up 0.02% of Aperio Group's portfolio in Q4 2020, its #626 holding.
- Aperio Group first reported a position in Core Laboratories in Q2 2013 and has held it in 30 quarters since.
- 181 funds tracked by Wall St. Rank held Core Laboratories as of Q4 2020.
Based on Aperio Group's 13F filing for Q4 2020, filed 5 Feb 2021.